Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population

Fakhruddin,Najla; Mahfouz,Rami; Farhat,Fadi; Tfayli,Arafat; Abdelkhalik,Rabab; Jabbour,Mark; Yehia,Lamis; Mahfoud,Ziyad; Zaatari,Ghazi

doi:10.3892/or.2014.3406

Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: A retrospective study of the Lebanese population

Authors:
- Najla Fakhruddin
- Rami Mahfouz
- Fadi Farhat
- Arafat Tfayli
- Rabab Abdelkhalik
- Mark Jabbour
- Lamis Yehia
- Ziyad Mahfoud
- Ghazi Zaatari
View Affiliations

Affiliations: Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Department of Hematology-Oncology, Hammoud Hospital University Medical Center, Sidon, Lebanon, Department of Hematology-Oncology, American University of Beirut Medical Center, Beirut, Lebanon, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA, Department of Public Health, Weill Cornell Medical College, Doha, Qatar
Published online on: August 14, 2014 https://doi.org/10.3892/or.2014.3406
Pages: 2223-2229

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular genetic analysis of epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) mutations in lung adenocarcinoma has become an integral part of lung cancer diagnosis and treatment; however, their prevalence varies with ethnicity. Little is know concerning their prevalence in Arab populations. In the present study, mutational analysis for EGFR and KRAS was performed on two cohorts of the Lebanese population. Lung adenocarcinoma cases (106) underwent mutational analysis for KRAS in exon 2, codon 12 and 13 and exon 3 codon 61 by reverse hybridization using the KRAS 12/13/61 StripAssay®. Subsequently, cases with no KRAS mutations underwent EGFR mutational analysis using the EGFR RGQ polymerase chain reaction (PCR) kits for real‑time PCR on the Rotor‑Gene Q 5-plex HRM. KRAS mutations were detected in 37.7% of 106 lung adenocarcinomas; 85% had a G>T substitution in codon 12 and 13 of exon 2, and 8.5% had EGFR mutations with exon 19 deletions (88.9%) and one case with L858R substitution in exon 21. EGFR mutations were significantly correlated with females, non-smokers and well differentiation of the tumor. This is the first study in an Arab population that reports the prevalence of both EGFR and KRAS gene mutations in lung adenocarcinoma using very sensitive mutational analysis techniques. Therefore, EGFR reflex testing should be implemented in the management of lung adenocarcinomas, while KRAS testing must await the identification of effective targeted therapy.

View Figures

View References

1	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
2	Salim EI, Moore MA, Al-Lawati JA, et al: Cancer epidemiology and control in the Arab world - past, present and future. Asian Pac J Cancer Prev. 10:3–16. 2009.PubMed/NCBI
3	Salim EI, Jazieh AR and Moore MA: Lung cancer incidence in the Arab league countries: risk factors and control. Asian Pac J Cancer Prev. 12:17–34. 2011.PubMed/NCBI
4	Ministry of Public Health (MOPH) L. Literature review report on selected diseases in Lebanon. 2004.
5	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
6	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar
7	Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005. View Article : Google Scholar : PubMed/NCBI
8	Wang Y, Schmid-Bindert G and Zhou C: Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol. 4:19–29. 2012. View Article : Google Scholar : PubMed/NCBI
9	Ahmed SM and Salgia R: Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology. 11:687–692. 2006. View Article : Google Scholar : PubMed/NCBI
10	Lindeman NI, Cagle PT, Beasley MB, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 137:828–860. 2013.
11	Kiaris H and Spandidos D: Mutations of ras genes in human tumours (Review). Int J Oncol. 3:413–421. 1995.
12	Riely GJ, Marks J and Pao W: KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 6:201–205. 2009. View Article : Google Scholar : PubMed/NCBI
13	Roberts PJ, Stinchcombe TE, Der CJ and Socinski MA: Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 28:4769–4777. 2010.PubMed/NCBI
14	Centers for Disease Control and Prevention (CDC). Lung cancer rates decline nationwide. 2011, http://www.cdc.gov/media/releases/2011/p0915_lung_cancer.html.
15	Cancer Research UK. Lung cancer incidence statistics. 2013, http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/incidence/uk-lung-cancer-incidence-statistics.
16	Underwood JM, Townsend JS, Tai E, et al: Racial and regional disparities in lung cancer incidence. Cancer. 118:1910–1918. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhou W and Christiani DC: East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 30:287–292. 2011. View Article : Google Scholar : PubMed/NCBI
18	Greulich H: The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes Cancer. 1:1200–1210. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12:735–742. 2011.PubMed/NCBI
20	Travis WD, Brambilla E, Noguchi M, et al: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar
21	Al-Kuraya K, Siraj AK, Bavi P, et al: High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol. 37:453–457. 2006. View Article : Google Scholar : PubMed/NCBI
22	Wu CC, Hsu HY, Liu HP, et al: Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer. 113:3199–3208. 2008.PubMed/NCBI
23	Szumera-Cieckiewicz A, Olszewski WT, Tysarowski A, et al: EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. Int J Clin Exp Pathol. 6:2800–2812. 2013.
24	Dogan S, Shen R, Ang DC, et al: Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 18:6169–6177. 2012.
25	Reinersman JM, Johnson ML, Riely GJ, et al: Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol. 6:28–31. 2011.PubMed/NCBI
26	Arrieta O, Cardona AF, Federico Bramuglia G, et al: Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol. 6:1955–1959. 2011. View Article : Google Scholar : PubMed/NCBI
27	Gazdar AF, Shigematsu H, Herz J and Minna JD: Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med. 10:481–486. 2004.PubMed/NCBI
28	Kim YT, Kim TY, Lee DS, et al: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer. 59:111–118. 2008. View Article : Google Scholar : PubMed/NCBI
29	Godin-Heymann N, Bryant I, Rivera MN, et al: Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 67:7319–7326. 2007. View Article : Google Scholar : PubMed/NCBI
30	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
31	Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 14:5731–5734. 2008.PubMed/NCBI
32	Bos JL: ras oncogenes in human cancer: a review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
33	Okudela K, Woo T and Kitamura H: KRAS gene mutations in lung cancer: particulars established and issues unresolved. Pathol Int. 60:651–660. 2010. View Article : Google Scholar : PubMed/NCBI
34	Siegfried JM, Gillespie AT, Mera R, et al: Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 6:841–847. 1997.PubMed/NCBI
35	Johnson ML, Sima CS, Chaft J, et al: Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 119:356–362. 2013.
36	Dacic S: EGFR assays in lung cancer. Adv Anat Pathol. 15:241–247. 2008. View Article : Google Scholar : PubMed/NCBI
37	Jancik S, Drabek J, Berkovcova J, et al: A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res. 31:792012. View Article : Google Scholar : PubMed/NCBI
38	Fong KM, Zimmerman PV and Smith PJ: KRAS codon 12 mutations in Australian non-small cell lung cancer. Aust NZ J Med. 28:184–189. 1998. View Article : Google Scholar : PubMed/NCBI
39	Tam IY, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 12:1647–1653. 2006.PubMed/NCBI
40	Bae NC, Chae MH, Lee MH, et al: EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genet Cytogenet. 173:107–113. 2007. View Article : Google Scholar
41	Kosaka T, Yatabe Y, Onozato R, Kuwano H and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol. 4:22–29. 2009.
42	Jang TW, Oak CH, Chang HK, Suo SJ and Jung MH: EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 24:48–54. 2009. View Article : Google Scholar : PubMed/NCBI
43	Boldrini L, Ali G, Gisfredi S, et al: Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncol Rep. 22:683–691. 2009.PubMed/NCBI
44	Xu J, He J, Yang H, et al: Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark. 10:63–69. 2011.PubMed/NCBI
45	Kakegawa S, Shimizu K, Sugano M, et al: Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer. 117:4257–4266. 2011. View Article : Google Scholar : PubMed/NCBI
46	Smits AJ, Kummer JA, Hinrichs JW, et al: EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol. 35:189–196. 2012. View Article : Google Scholar
47	Bacchi CE, Ciol H, Queiroga EM, Benine LC, Silva LH and Ojopi EB: Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics. 67:419–424. 2012. View Article : Google Scholar : PubMed/NCBI
48	Guan JL, Zhong WZ, An SJ, et al: KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol. 20:1381–1388. 2013. View Article : Google Scholar : PubMed/NCBI
49	Fiala O, Pesek M, Finek J, Benesova L, Belsanova B and Minarik M: The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Genet. 206:26–31. 2013.PubMed/NCBI
50	Unal OU, Oztop I, Calibasi G, et al: Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey. Asian Pac J Cancer Prev. 14:3705–3709. 2013. View Article : Google Scholar : PubMed/NCBI
51	Choi YL, Sun JM, Cho J, et al: EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. PloS One. 8:e560112013. View Article : Google Scholar